Posology : מינונים

DOSAGE AND ADMINISTRATION
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. The vial and its packaging should be inspected prior to use for evidence of leakage or a faulty seal. If evidence of such defects are observed, the vaccine should not be used. Do not remove the vial stopper or the metal seal holding it in place.
After preparation of the injection site, using a suitable sterile needle and aseptic technique, immediately administer IMOVAX POLIO vaccine intramuscularly or subcutaneously. In infants and small children, the mid-lateral aspect of the thigh is the preferred site. In older children and adults, IMOVAX POLIO vaccine should be administered intramuscularly or subcutaneously in the deltoid area. IMOVAX POLIO should not be combined through reconstitution or mixed with any other vaccine.
To help avoid HIV (AIDS), HBV (Hepatitis), and other infectious diseases due to accidental needlesticks, contaminated needles should not be recapped or removed, unless there is no alternative or that such action is required by a specific medical procedure.
Care should be taken to avoid administering the injection into or near blood vessels and nerves. If blood or any suspicious discoloration appears in the syringe, do not inject but discard contents and repeat procedures using a new dose of vaccine administered at a different site.

DO NOT ADMINISTER VACCINE INTRAVENOUSLY.
Children
The primary series of IMOVAX POLIO vaccine consists of three 0.5 mL doses administered intramuscularly or subcutaneously, preferably eight or more weeks apart and usually at ages 2, 4, and 6 to 18 months. Under no circumstances should the vaccine be given more frequently than four weeks apart. The first immunization may be administered as early as six weeks of age.

Use with Other Vaccines
From historical data on the antibody responses to diphtheria, tetanus, whole-cell or acellular pertussis, Hib, or hepatitis B vaccines used concomitantly with IMOVAX POLIO vaccine, no interferences have been observed on the immunological end points accepted for clinical protection.
(See DRUG INTERACTIONS section.)
If the third dose of IMOVAX POLIO vaccine is given between 12 to 18 months of age, it may be desirable to administer this dose with Measles, Mumps, and Rubella (MMR) vaccine and/or other vaccines using separate syringes at separate sites, but no data on the immunological interference between IMOVAX POLIO vaccine and these vaccines exist.
Use in Previously Vaccinated Children
Children and adolescents with a previously incomplete series of polio vaccine should receive sufficient additional doses of IMOVAX POLIO vaccine to complete the series.
Interruption of the recommended schedule with a delay between doses does not interfere with the final immunity. There is no need to start the series over again, regardless of the time elapsed between doses.
The need to routinely administer additional doses is unknown at this time.

Adults
Unvaccinated Adults
A primary series of IMOVAX POLIO vaccine is recommended for unvaccinated adults at increased risk of exposure to poliovirus. While the responses of adults to primary series have not been studied, the recommended schedule for adults is two 0.5 mL doses given at a 1 to 2 month interval and a third 0.5 mL dose given 6 to 12 months later. If less than 3 months but more than 2 months are available before protection is needed, three doses of IMOVAX POLIO vaccine should be given at least 1 month apart. Likewise, if only 1 or 2 months are available, two 0.5 mL doses of IMOVAX POLIO vaccine should be given at least 1 month apart. If less than 1 month is available, a single 0.5 mL dose of IMOVAX POLIO vaccine is recommended.

Incompletely Vaccinated Adults
Adults who are at an increased risk of exposure to poliovirus and who have had at least one dose of OPV, fewer than three doses of conventional IPV or a combination of conventional IPV or OPV totaling fewer than three doses should receive at least one 0.5 mL dose of IMOVAX POLIO vaccine.
Additional doses needed to complete a primary series should be given if time permits.

Completely Vaccinated Adults
Adults who are at an increased risk of exposure to poliovirus and who have previously completed a primary series with one or a combination of polio vaccines can be given a 0.5 mL dose of IMOVAX POLIO vaccine.
The preferred injection site of IMOVAX POLIO vaccine for adults is in the deltoid area.